News

Janssen will carry out a phase 2 trial, which will test the tolerability and clinical activity of its investigational immunotherapy JNJ-64041757 with BMS’ PD-1 immune checkpoint inhibitor, Opdivo

The US Food and Drug Administration (FDA) has granted V920 a breakthrough therapy designation which aims to expedite the development and review of a candidate that is planned

The Series C round, which brings Tricida’s total financing to $95M, was led by new investor Longitude Capital. New investor Vivo Capital and existing investors OrbiMed, Sibling Capital

As previously disclosed, in January 2016 Novartis informed GenVec that enrollment in the trial had been paused in accordance with criteria in the trial's protocol.  In April 2016,

The Bill & Melinda Gates Foundation led the financing with an $8M investment followed by $2M each from existing investors Merck, Lilly Asia Ventures and ARCH Venture Partners. The proceeds

The ULTRA study will evaluate the effects of ubenimex in patients with secondary lymphedema of the lower limb(s) who are optimized on physical therapies.  Physical therapies, such as

All Series A investors contributed to the financing extension, including Alexandria Venture Investments, Bay City Capital LLC, Lundbeckfond Ventures, New Enterprise Associates (NEA), and Pfizer Venture Investments. Together

The phase 1/2 clinical trial will evaluate the safety, tolerability, and efficacy of BMS’s Opdivo and Opdivo + Yervoy in conjunction with AbbVie’s Rova-T, a delta-like protein 3

Valeant has received a complete response letter (CRL) from the FDA for latanoprostene bunod (LBN) ophthalmic solution 0.024%, an intraocular pressure lowering single-agent eye drop for patients with